BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 32820120)

  • 21. B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma.
    Wang Y; Ji N; Zhang Y; Chu J; Pan C; Zhang P; Ma W; Zhang X; Xi JJ; Chen M; Zhang Y; Zhang L; Sun T
    J Transl Med; 2023 Sep; 21(1):672. PubMed ID: 37770968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer.
    Ji N; Mukherjee N; Shu ZJ; Reyes RM; Meeks JJ; McConkey DJ; Gelfond JA; Curiel TJ; Svatek RS
    Cancer Immunol Res; 2021 Dec; 9(12):1491-1503. PubMed ID: 34607803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Butyrophilin-like proteins display combinatorial diversity in selecting and maintaining signature intraepithelial γδ T cell compartments.
    Jandke A; Melandri D; Monin L; Ushakov DS; Laing AG; Vantourout P; East P; Nitta T; Narita T; Takayanagi H; Feederle R; Hayday A
    Nat Commun; 2020 Jul; 11(1):3769. PubMed ID: 32724083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosurveillance by human γδ T lymphocytes: the emerging role of butyrophilins.
    Kabelitz D; Lettau M; Janssen O
    F1000Res; 2017; 6():. PubMed ID: 28649364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ligand-induced interactions between butyrophilin 2A1 and 3A1 internal domains in the HMBPP receptor complex.
    Hsiao CC; Nguyen K; Jin Y; Vinogradova O; Wiemer AJ
    Cell Chem Biol; 2022 Jun; 29(6):985-995.e5. PubMed ID: 35081362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2
    Lai AY; Patel A; Brewer F; Evans K; Johannes K; González LE; Yoo KJ; Fromm G; Wilson K; Schreiber TH; de Silva S
    J Immunol; 2022 Oct; 209(8):1475-1480. PubMed ID: 36096643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of Human γδ T Cells by BTN3A1 Protein Stability and ATP-Binding Cassette Transporters.
    Rhodes DA; Chen HC; Williamson JC; Hill A; Yuan J; Smith S; Rhodes H; Trowsdale J; Lehner PJ; Herrmann T; Eberl M
    Front Immunol; 2018; 9():662. PubMed ID: 29670629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vγ9Vδ2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6.
    Riaño F; Karunakaran MM; Starick L; Li J; Scholz CJ; Kunzmann V; Olive D; Amslinger S; Herrmann T
    Eur J Immunol; 2014 Sep; 44(9):2571-6. PubMed ID: 24890657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain.
    Salim M; Knowles TJ; Baker AT; Davey MS; Jeeves M; Sridhar P; Wilkie J; Willcox CR; Kadri H; Taher TE; Vantourout P; Hayday A; Mehellou Y; Mohammed F; Willcox BE
    ACS Chem Biol; 2017 Oct; 12(10):2631-2643. PubMed ID: 28862425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune recognition of phosphoantigen-butyrophilin molecular complexes by γδ T cells.
    Uldrich AP; Rigau M; Godfrey DI
    Immunol Rev; 2020 Nov; 298(1):74-83. PubMed ID: 33017054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Murine T cell determination of pregnancy outcome: I. Effects of strain, alphabeta T cell receptor, gammadelta T cell receptor, and gammadelta T cell subsets.
    Arck PC; Ferrick DA; Steele-Norwood D; Croitoru K; Clark DA
    Am J Reprod Immunol; 1997 Jun; 37(6):492-502. PubMed ID: 9228307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation.
    Gu S; Sachleben JR; Boughter CT; Nawrocka WI; Borowska MT; Tarrasch JT; Skiniotis G; Roux B; Adams EJ
    Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7311-E7320. PubMed ID: 28807997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of cytokine producing activity of intestinal intraepithelial T cells from TCR beta-chain and delta-chain mutant mice.
    Kohyama M; Hachimura S; Nanno M; Ishikawa H; Kaminogawa S
    Microbiol Immunol; 1997; 41(4):353-9. PubMed ID: 9159410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies.
    Palakodeti A; Sandstrom A; Sundaresan L; Harly C; Nedellec S; Olive D; Scotet E; Bonneville M; Adams EJ
    J Biol Chem; 2012 Sep; 287(39):32780-90. PubMed ID: 22846996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation.
    Starick L; Riano F; Karunakaran MM; Kunzmann V; Li J; Kreiss M; Amslinger S; Scotet E; Olive D; De Libero G; Herrmann T
    Eur J Immunol; 2017 Jun; 47(6):982-992. PubMed ID: 28386905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells.
    Vavassori S; Kumar A; Wan GS; Ramanjaneyulu GS; Cavallari M; El Daker S; Beddoe T; Theodossis A; Williams NK; Gostick E; Price DA; Soudamini DU; Voon KK; Olivo M; Rossjohn J; Mori L; De Libero G
    Nat Immunol; 2013 Sep; 14(9):908-16. PubMed ID: 23872678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. γδ T cell-mediated cytotoxicity against patient-derived healthy and cancer cervical organoids.
    Dong J; Holthaus D; Peters C; Koster S; Ehsani M; Quevedo-Olmos A; Berger H; Zarobkiewicz M; Mangler M; Gurumurthy RK; Hedemann N; Chumduri C; Kabelitz D; Meyer TF
    Front Immunol; 2023; 14():1281646. PubMed ID: 38090581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
    Liu Z; Guo B; Lopez RD
    J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
    Miyashita M; Shimizu T; Ashihara E; Ukimura O
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigen recognition by human γδ T cells: one step closer to knowing.
    Eberl M
    Immunol Cell Biol; 2020 May; 98(5):351-354. PubMed ID: 32329107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.